Briacell Therap (NASDAQ:BCTX) Sees Significant Increase in Short Interest

Briacell Therap (NASDAQ:BCTX) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 723,836 shares, an increase of 81.5% from the August 15th total of 398,913 shares. Approximately 8.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 967,776 shares, the days-to-cover ratio is currently 0.7 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Briacell Therap in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Briacell Therap Trading Down 1.6%

BCTX opened at $3.52 on Wednesday. The company has a fifty day simple moving average of $3.62 and a 200 day simple moving average of $3.71. The firm has a market cap of $30.63 million, a price-to-earnings ratio of -0.44 and a beta of 1.10. Briacell Therap has a twelve month low of $2.60 and a twelve month high of $14.68.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.